ArticleGastroenterology report2021
An 11-gene signature for the prediction of systemic recurrences in colon adenocarcinoma.
Article in Gastroenterology report, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Fatty acid-binding protein 4 as a biomarker for colon adenocarcinoma risk and prognosis: Challenges and future directions.World journal of gastrointestinal oncology · 2025Article
- Proteomics-based prognostic signature in colon adenocarcinoma patients with familial adenomatous polyposis.Translational cancer research · 2025Article
- Article
- Prospective and Mendelian randomization analyses on the association of circulating fatty acid binding protein 4 (FABP-4) and risk of colorectal cancer.BMC medicine · 2023Article
- Establishment and validation of a ferroptosis-related signature predicting prognosis and immunotherapy effect in colon cancer.Frontiers in oncology · 2023Article
- A novel prognostic model based on urea cycle-related gene signature for colorectal cancer.Frontiers in surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrognosis varies among patients within the same colon adenocarcinoma (COAD) stage, indicating the need for reliable molecular markers to enable individualized treatment. This study aimed to investigate gene signatures that can be used for better prognostic prediction of COAD.
methodsGene-expression profiles of COAD patients were obtained from the Gene Expression Omnibus database (
resultsOverall, 11 genes (N-myc downstream regulated gene 1 [
conclusionsThe 11-gene signature showed good performance in predicting recurrence in COAD. The accuracy of the signature for prognostic classification requires further confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.